Could a platelet-boosting drug shorten recovery after stem cell transplants?
NCT ID NCT07747246
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study looks back at medical records of people who had an allogeneic stem cell transplant to see whether romiplostim helped their platelets recover faster. Platelets are blood cells that help clotting, and low counts are common after transplant. The researchers will compare platelet recovery times, transfusion needs, and safety in patients who received romiplostim versus those who did not. No new treatments are being given; the study simply reviews what happened.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If the data show a benefit, romiplostim could become a standard option to speed platelet recovery and reduce transfusion needs after stem cell transplants.
- What could go wrong
- Because this is a retrospective review, it can only suggest associations, not prove cause and effect. Results may be influenced by missing data or patient differences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Dual-Action pill tame bone marrow tumors?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can a new pill shrink the spleen in myelofibrosis?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?